EV5246 SO7US
Express Mail Label Number

20. Other items or information:

May La 505

Date of Deposit

Form PTO- (REV 10-9		. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER								
	TRANSMITTAL LETTER TO T DESIGNATED/ELECTED OF CONCERNING A FILING UP	FFICE (DO/EO/US)	DC/4-32652A U.S. APPLICATION NO. (If known, see 37 CFR 1.5)  10/534966								
INTER	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
PCT/EP2003/013715		4 December 2003 (04.12.03)	5 December 2002 (05.12.02)								
	OF INVENTION										
	ING METHODOLOGY COMPRISING	OLIGOPEPTIDES	The state of the s								
	CANT(S) FOR DO/EO/US ET AL.		·								
1. 🛭 2. 🔲	nt herewith submits to the United States D  This is a FIRST submission of items con This is a SECOND or SUBSEQUENT su This express request to begin national ex	cerning a filing under 35 U.S.C. 371.  Ibmission of items concerning a filing university in the concerning and the concerning a	der 35 U.S.C. 371. )) at any time rather than delay								
4. 🛛	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.										
5. 🖾	A copy of the International Application as filed (35 U.S.C. 371(c)(2))  a.  is transmitted herewith (required only if not transmitted by the International Bureau).  b.  has been transmitted by the International Bureau. (See Form PCT/IB/308)  c.  is not required, as the application was filed in the United States Receiving Office (RO/US).										
6. ∐ 7. ⊠	A translation of the International Application into English (35 U.S.C. 371(c)(2)).  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).  a.										
8. □ 9. ⊠ 10. □	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).  An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
items 1	1. to 16. below concern document(s) or	information included.									
11. 🛚	An Information Disclosure Statement und	der 37 CFR 1.97 and 1.98.									
	An assignment document for recording.	A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included.								
13 <b>2</b>	A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelimina	ry amendment.									
14. 🛚	An Application Data Sheet under 37 CFF	R 1.76.									
15. 🗌	A substitute specification.										
16. 🗌	A change of power of attorney and/or add	dress letter.									
17. 🛚	A computer-readable form of the sequen	ce listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821-1.825.								
18. 🔲	A second copy of the published Internation	onal Application under 35 U.S.C. 154(d)	(4).								
19. 🗌	A second copy of the English language to	ranslation of the International application	under 35 U.S.C. 154(d)(4).								

## JC20 Rec'd PCT/PTO 1 6 MAY 2005

U.S. APPLICATION NO. (if known, see 37 FF 1.8)  INTERNATIONAL APPLICATION NO. (if known, see 37 FF 1.8)  INTERNATIONAL APPLICATION NO. (if known, see 37 FF 1.8)  INTERNATIONAL APPLICATION NO. (if known, see 37 FF 1.8)						OCKET NUMBER				
The following fe	es are submitted:	المحيد						CAL	CULATIO	NS PTO USE
								ONLY		
21. 🛮 Basic national fee										
22. Examination Fee										
<ul> <li>If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)</li></ul>								i		
23. Search fee										
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$										
☑ If International Search Report was prepared and provided to the Office \$400										
All other situations										
TOTAL OF 21, 22 AND 23 =								\$	900	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction										
program listing f thereof.	nied in an electronic	medium). The	tee is \$250 for each add	iltiona	ai 50 s	sneets o	ot paper o	rractio	on	
Total Sheets	Extra sheets		ch additional 50 or fracti	on		RAT	E			
74 - 100 =	/50 =	thereof (round	l up to a whole number) 0		X	\$	250	\$		
Curcharge of \$4	30 for furnishing the	anth of doctor	ation later than   30							
months from the	e earliest claimed pr	ority date (37 C	FR 1.492(e)).					\$		
CLAIMS Total claims	NUMB 16	ER FILED - 20 =	NUMBER EXTRA 0	X	,	RATE	50	\$		
Independent cla	ims 3	- 3 =	0	<del> </del>		\$ \$	200	\$		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =								\$	900	,
Reduction of 1/2	2 for filing by small e	ntity, if applicat						Ψ   .	900	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).								\$	- 000	
SUBTOTAL =  Processing fee of \$130 for furnishing the English translation later than 30 months from the							\$	900		
	priority date (37 CF		`				+	\$		
Fac for reading	41	(27.OF					FEE =	\$	900	
	ig the enclosed assi te cover sheet (37 C		R 1.21(h)). The assignm . <b>\$40</b> per property	ent n	nust b	e accoi	mpanieo +	\$		
			TOTAL	. FEI	ES E	NCLC	SED =	\$	900	
									mount to refunded	\$
										\$
a. A chec	k in the amount of \$		to cover the above fe	es is	enclo	sed.				
	charge Deposit Acate copy of this form		34 in the name of Nova	rtis in	the a	mount o	of \$900 to	cover	the above	fees. A
			o charge any additional ( of Novartis.	ees v	vhich	may be	required,	or cred	dit any ove	erpayment to
Deposit Account No. 19-0134 in the name of Novartis.  NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
	-			//	7					
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
			Gre	gøŋ	QHO	oughton		V		<del>-</del>
Novartis Attorbéy for Applicants Corporate Intellectual Property Reg. No. 47,666										
One Health Plaza, Building 104 (862) 778-2614										
⊨ast Ha	inover, NJ 07936-10	10U								